REG - Assura plc - Board Change

AssuraAnnouncement

19/08/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250819:nRSS7996Va&default-theme=true

RNS Number : 7996V  Assura PLC  19 August 2025

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR
INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE
A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION

 

FOR IMMEDIATE RELEASE

 

19 August 2025

 

Assura plc ("Assura")

 

Board change

 

Assura announces that Ed Smith, CBE, Non-Executive Chair of Assura, has
informed the company that he is resigning from his office as a director and
Non-Executive Chair with immediate effect.

Ed Smith joined the Assura Board in 2017 and was appointed Chair in 2018.
During his time as Chair he has provided critical oversight of Assura's
strategy and governance, building on his extensive health service, public
sector and business experience. Through his strong leadership of the board,
Assura has been successful in delivering for its shareholders and its wider
stakeholder group, including the National Health Service.

The board of directors of Assura notes the offer for Assura by Primary Health
Properties PLC ("PHP"), which was declared wholly unconditional on 12 August
2025, and which currently remains open for acceptance until further notice. If
PHP acquires Assura shares carrying 75 per cent. or more of the voting rights
of Assura, PHP intends to procure the delisting and cancellation of trading of
Assura's shares from the London Stock Exchange and the Johannesburg Stock
Exchange.

In this context, the board of directors of Assura has appointed the Senior
Non-Executive Director, Jonathan Davies, as Chair.

Jonathan Murphy, Chief Executive Officer of Assura, commented:

"We sincerely thank Ed for his huge contribution to the success of Assura over
the past seven years. His guidance and support to me and the wider team has
been invaluable. I know that I can speak for everyone in Assura in wishing him
all the best for the future."

Jonathan Davies, Non-Executive Chair of Assura, commented:

"On behalf of the Board, I would like to thank Ed for his fantastic leadership
and stewardship of the business during his term as Chair. Ed has played a
vital role in driving Assura's performance and developing its long-term
strategy, whilst never losing focus on its strong social purpose and the need
to support the NHS. Both the Board and the wider business have been very
fortunate to benefit from his deep knowledge and experience of the health
sector. It has been a great privilege to work alongside Ed during all of his
term as Chair and I now look forward to leading the Board during the CMA
process."

Enquiries

 

Assura
plc
0161 515 2043

Jonathan Murphy

Jayne Cottam

 

FGS Global (PR Adviser to
Assura)
020 7251 3801

Gordon Simpson

Anjali Unnikrishnan

Grace Whelan

 

Inside Information

 

This Announcement contains inside information as defined in the UK version of
the Market Abuse Regulation (EU) No 596/2014, which is part of UK domestic law
by virtue of the European Union (Withdrawal) Act 2018. Upon the publication of
this Announcement via a Regulatory Information Service, such inside
information will be considered to be in the public domain.

 

The person responsible for arranging the release of this Announcement on
behalf of Assura is Orla Ball, Company Secretary and General Counsel.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAPKFBNFBKDKFD